Renascience Inc. (4889.T) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 5Aug 10Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−33.7x

Market Cap

JPY 14.49B

MomentumView details →

1D Return

−1.13%

YTD Return

−15.75%

RSI (14)

40.5

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−33.7x

Market Cap

JPY 14.49B

RSI (14)

40.5

MomentumView details →

1D Return

−1.13%

YTD Return

−15.75%

ProfitabilityView details →

Gross Margin

94.42%

Net Margin

−442.65%

EBITDA Margin

—

ROE (TTM)

−9.06%

ROA (TTM)

−8.59%

Asset Turnover

0.02x

GrowthView details →

Revenue YoY

−48.48%

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

−12.06%

EPS CAGR 3Y

—

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

—

Current Ratio

19.40x

Quick Ratio

19.40x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

68.00M

Net Income (TTM)

−301.00M

Op. CF (TTM)

—

Next earningsNov 5, 2026 →

Latest newsMore news →

Renascience Inc. has initiated a Phase 2 clinical trial of its PAI-1 inhibitor RS5614 for locally advanced non-small cell lung cancer.45d ago

Renascience announced the start of a Phase II physician-led trial of PAI-1 inhibitor RS5614 in combination with chemoradiotherapy and durvalumab for locally advanced non-small cell lung cancer, with first patient dosed on July 16, 2026.46d ago

Similar companies

AnGes,Inc.4563.T CanBas Co.,Ltd.4575.T RaQualia Pharma Inc.4579.T TAIKO PHARMACEUTICAL CO.,LTD.4574.T STELLA PHARMA CORPORATION4888.T MediciNova,Inc.4875.T Find similar companies →

Latest newsMore news →

Renascience Inc. has initiated a Phase 2 clinical trial of its PAI-1 inhibitor RS5614 for locally advanced non-small cell lung cancer.45d ago Renascience announced the start of a Phase II physician-led trial of PAI-1 inhibitor RS5614 in combination with chemoradiotherapy and durvalumab for locally advanced non-small cell lung cancer, with first patient dosed on July 16, 2026.46d ago